Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma

Kenneth R. Carson, Peter Riedell, Ryan Lynch, Chadi Nabhan, Tanya M. Wildes, Weijian Liu, Arun Ganti, Ryan Roop, Kristen M. Sanfilippo, Katiuscia O'Brian, Jingxia Liu, Nancy L. Bartlett, Amanda Cashen, Nina Wagner-Johnston, Todd A. Fehniger, Graham A. Colditz

Research output: Contribution to journalArticle

Abstract

Objectives: While anthracycline-based treatment can cure diffuse large B-cell lymphoma, most patients over age 80 do not receive doxorubicin due to toxicity concerns. This study evaluated this practice, as patients age 80 and older are largely excluded from clinical trials. The primary outcome of interest was overall survival. Secondary outcomes included treatment-related mortality and anthracycline dose intensity. Materials and Methods: We assembled a cohort of 530 newly diagnosed diffuse large B-cell lymphoma patients age 80 or older diagnosed within United States Veterans Health Administration. Treatment and survival information were obtained to determine associations between anthracycline use, dose intensity, treatment-related mortality and overall survival. Results: Of the 530 patients, 285 received systemic treatment and 193 received an anthracycline. After controlling for potential confounders, rituximab decreased mortality (hazard ratio, 0.62; 95% confidence interval [CI]: 0.44-0.88), while doxorubicin was not significantly associated with mortality (hazard ratio, 0.87; 95% CI: 0.64-1.17). Completion of treatment with anthracycline dose intensity ≥ 85% of expected was only 14%. Patients treated with anthracycline dose intensity < 85% had better one year survival compared to those treated at ≥ 85% (70% vs. 59%, p = 0.029). Conclusion: These results suggest that full dose anthracycline therapy may be less important in the treatment of diffuse large B-cell lymphoma patients over age 80. The low frequency of completion of full dose intensity treatment suggests that standard doses are an unrealistic standard of care for patients this age. Alternate treatment strategies and risk stratification should be considered for these patients.

Original languageEnglish (US)
Pages (from-to)211-218
Number of pages8
JournalJournal of Geriatric Oncology
Volume6
Issue number3
DOIs
StatePublished - May 1 2015

Keywords

  • Doxorubicin
  • Elderly
  • Lymphoma
  • Veterans

ASJC Scopus subject areas

  • Oncology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Carson, K. R., Riedell, P., Lynch, R., Nabhan, C., Wildes, T. M., Liu, W., Ganti, A., Roop, R., Sanfilippo, K. M., O'Brian, K., Liu, J., Bartlett, N. L., Cashen, A., Wagner-Johnston, N., Fehniger, T. A., & Colditz, G. A. (2015). Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. Journal of Geriatric Oncology, 6(3), 211-218. https://doi.org/10.1016/j.jgo.2015.01.003